Prospektív, multicentrikus, randomizált kontrollált vizsgálat a koszorúér CT angiográfia értékének feltárására a koszorúér-kalcium megértésében és kezelésében (Az Optimális Vizsgálat)
Egy prospektív, multicentrikus, randomizált kontrollált vizsgálat a koszorúér CT angiográfia értékének vizsgálatára a koszorúér kalcium megértésében és kezelésében
The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
The OPTIMAL Trial is a prospective, multicenter, randomized controlled study evaluating whether a coronary CT angiography (CCTA)-guided calcium modification strategy can improve the treatment of patients with hemodynamically significant, calcified coronary artery disease undergoing percutaneous coronary intervention (PCI).
Seven hundred patients with flow-limiting stenosis (FFRCT ≤0.80) and moderate-to-severe calcification on CCTA will be randomized 1:1 to either CCTA-guided or intravascular ultrasound (IVUS)-guided calcium modification. The study includes two co-primary endpoints: (1) superiority in final minimal stent area assessed by IVUS, and (2) non-inferiority in 12-month target vessel failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven revascularization).
CCTA-guided strategy uses advanced calcium characterization to inform pre-procedural planning and selection of plaque modification techniques. IVUS-guided strategy follows contemporary intravascular imaging-based criteria for plaque preparation and PCI optimization.
The trial aims to determine whether leveraging non-invasive CT-based calcium assessment can enhance procedural efficiency and stent results while maintaining clinical safety comparable to IVUS-guided PCI.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: CAROLINA FOCELLA
- Telefonszám: 001 917 753 6695
- E-mail: cfocella@crf.org
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: CARLOS COLLET, MD,PhD
- Telefonszám: 001 917 753 6695
- E-mail: carloscollet@gmail.com
Tanulmányi helyek
-
-
-
Aalst, Belgium, 9300
- Toborzás
- Azorg Hospital, Aalst
-
-
-
-
-
Leicester, Egyesült Királyság
- Toborzás
- University Hospitals of Leicester NHS Trust
-
London, Egyesült Királyság
- Toborzás
- St Bartholomew's Hospital (Barts Health NHS Trust)
-
London, Egyesült Királyság
- Toborzás
- St George's University Hospitals NHS Foundations Trust
-
Kapcsolatba lépni:
- James Spratt, MD, PhD
-
London, Egyesült Királyság
- Toborzás
- Guys & St Thomas Nhs Foundation Trust
-
Newcastle, Egyesült Királyság
- Még nincs toborzás
- Newcastle Hospitals NHS Foundations Trust
-
Oxford, Egyesült Királyság
- Még nincs toborzás
- John Radcliffe Hospital, Oxford
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02115
- Még nincs toborzás
- Bringham and Women's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Egyesült Államok, 55407
- Toborzás
- Minneapolis Heart Institute
-
-
New Jersey
-
Jersey City, New Jersey, Egyesült Államok, 08837
- Még nincs toborzás
- HACKENSACK MERIDIAN HEALTH, Inc
-
-
New York
-
New York, New York, Egyesült Államok, 10032
- Toborzás
- Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
-
New York, New York, Egyesült Államok, 14853
- Még nincs toborzás
- Weill Medical College of Cornell University
-
-
-
-
-
Barcelona, Spanyolország, 08035
- Toborzás
- Hospital Universitari Vall Hebron
-
León, Spanyolország
- Toborzás
- Hospital Universitario de Leon
-
Madrid, Spanyolország, 28046
- Toborzás
- Hospital Universitario La Paz
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- The subject must be at least 18 years of age and younger than 85 years old
- Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score>140.
- All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm
- Subject must provide written informed consent before any study-related procedure
Exclusion Criteria:
- STEMI as the clinical presentation.
- Uncontrolled or recurrent ventricular tachycardia.
- Hemodynamic instability.
- Hemodialysis or peritoneal dialysis.
- Left main coronary artery stenosis > 50%
- Atrial fibrillation, flutter, or arrhythmias during CT acquisition.
- Previous PCI in the target vessel or CABG.
- BMI ≥ 40 kg/m2
- Insufficient CT quality assessed by the Core lab.
- Comorbidity with life expectancy ≤ 2 years.
- Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.
- The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.
- The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
- The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest/mediastinum.
- Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
- The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.
- The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy <2 years for any non-cardiac cause.
- Subject is currently participating in another investigational drug or device clinical study.
- Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
- Unable to provide written informed consent (IC).
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: CT-guide calcium modification strategy
Pre-procedural CT will be used to determine lesion characteristics. |
CT will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent |
|
Aktív összehasonlító: IVUS-guide calcium modification strategy
Pre-procedural IVUS will be used to determine lesion characteristics. |
IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Demonstrate that CT-guided calcium modification results in a superior final MSA Minimal Stent Area (MSA) - Imaging Endpoint (Superiority)
Időkeret: Perioperative/Periprocedural
|
Final post-PCI minimal stent area per target lesion, measured by independent core laboratory using intravascular ultrasound (IVUS). Assesses whether CT-guided calcium modification results in superior stent expansion compared with IVUS-guided PCI. |
Perioperative/Periprocedural
|
|
Target Vessel Failure (TVF) - Clinical Endpoint (Non-Inferiority)
Időkeret: 12 months
|
Composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR). TV-MI and ID-TVR are defined according to ARC-2 and the Fourth Universal Definition of MI. |
12 months
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Procedural efficiency: Procedure time
Időkeret: During PCI
|
Time from first angiogram to final angiogram |
During PCI
|
|
Procedural efficiency:Radiation dose-area product
Időkeret: During PCI
|
Dose-area product (DAP) recorded during PCI. |
During PCI
|
|
Procedural efficiency: Contrast volume
Időkeret: During PCI
|
Total contrast volume (mL) used during PCI.IVUS-Derived Mechanistic Endpoints (Core Lab) |
During PCI
|
|
Procedural Efficiency: Stent Area on Immediate Post-Stent IVUS
Időkeret: Perioperative/Periprocedural
|
MSA prior to any final IVUS-guided optimization. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Original Minimal Lumen Area (MLA)
Időkeret: Perioperative/Periprocedural
|
Stent area at the co-registered site of the baseline MLA. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Arc
Időkeret: Perioperative/Periprocedural
|
Stent area measured at the co-registered IVUS site with maximal calcium arc |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Density
Időkeret: Perioperative/Periprocedural
|
Stent area measured at the co-registered CT-identified region of greatest Hounsfield Unit (HU) calcium density. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Relative Stent Expansion
Időkeret: Perioperative/Periprocedural
|
Percentage expansion calculated as: MSA ÷ mean distal reference lumen area × 100. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Number of Calcium Fractures
Időkeret: Post-modification, pre-stent
|
Fractures identified on intermediary IVUS after calcium modification. |
Post-modification, pre-stent
|
|
Procedural Efficiency: Change in Plaque Attenuation
Időkeret: Post-modification, pre-stent
|
Change in IVUS plaque characteristics following calcium modification.Angiographic Endpoints |
Post-modification, pre-stent
|
|
Procedural Efficiency: Final Minimal Lumen Diameter
Időkeret: Perioperative/Periprocedural
|
Minimum lumen diameter by quantitative coronary angiography (QCA) |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Percent Diameter Stenosis
Időkeret: Perioperative/Periprocedural
|
Percent stenosis of treated lesion after PCI, by QCA |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final TIMI Flow Grade
Időkeret: Perioperative/Periprocedural
|
Target vessel flow graded 0-3 based on TIMI criteria. Thrombolysis In Myocardial Infarction (TIMI) Flow Grade is a 0-3 angiographic scale used during coronary angiography to describe how well blood is flowing through a coronary artery.TIMI 0 No perfusion, TIMI 1 Penetration without perfusion, TIMI 2 Partial perfusion TIMI 3 Complete perfusion (normal flow) |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Angiographic Complications
Időkeret: Day of procedure
|
According to Coronary dissection (NHLBI classification) |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
Időkeret: Day of procedure
|
According to Coronary perforation (Ellis classification) |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
Időkeret: Day of procedure
|
Slow-flow / no-reflow |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
Időkeret: Day of procedure
|
Side branch closure (TIMI 0-1) |
Day of procedure
|
|
Clinical & Safety Outcomes: Procedural Success
Időkeret: Perioperative/Periprocedural
|
Final stenosis <30%, TIMI 3 flow, no angiographic complications, and no in-hospital major adverse cardiac events (MACE). |
Perioperative/Periprocedural
|
|
Clinical & Safety Outcomes: Periprocedural Myocardial Infarction (Type 4a MI)
Időkeret: Day 0-1
|
Defined by ARC-2 and 4th Universal Definition of MI (troponin criteria + evidence of ischemia). |
Day 0-1
|
|
Clinical & Safety Outcomes: Stent Thrombosis
Időkeret: Up to 12 months
|
Definite or probable stent thrombosis according to ARC-2 definitions. |
Up to 12 months
|
|
Patient-Reported Outcomes: Residual Angina (SAQ-7 Angina Frequency)
Időkeret: 12 months
|
Residual angina defined as SAQ-7 Angina Frequency score <100. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently |
12 months
|
|
Patient-Reported Outcomes: Change in Angina (SAQ-7)
Időkeret: Baseline to 12 months
|
Change in angina frequency domain score; positive values indicate improvement. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently |
Baseline to 12 months
|
Együttműködők és nyomozók
Publikációk és hasznos linkek
Általános kiadványok
- Collet C, Sonck J, Vandeloo B, Mizukami T, Roosens B, Lochy S, Argacha JF, Schoors D, Colaiori I, Di Gioia G, Kodeboina M, Suzuki H, Van 't Veer M, Bartunek J, Barbato E, Cosyns B, De Bruyne B. Measurement of Hyperemic Pullback Pressure Gradients to Characterize Patterns of Coronary Atherosclerosis. J Am Coll Cardiol. 2019 Oct 8;74(14):1772-1784. doi: 10.1016/j.jacc.2019.07.072.
- Sonck J, Nagumo S, Norgaard BL, Otake H, Ko B, Zhang J, Mizukami T, Maeng M, Andreini D, Takahashi Y, Jensen JM, Ihdayhid A, Heggermont W, Barbato E, Mileva N, Munhoz D, Bartunek J, Updegrove A, Collinsworth A, Penicka M, Van Hoe L, Leipsic J, Koo BK, De Bruyne B, Collet C. Clinical Validation of a Virtual Planner for Coronary Interventions Based on Coronary CT Angiography. JACC Cardiovasc Imaging. 2022 Jul;15(7):1242-1255. doi: 10.1016/j.jcmg.2022.02.003. Epub 2022 Apr 13.
- Tajima A, Bouisset F, Ohashi H, Sakai K, Mizukami T, Rizzini ML, Gallo D, Chiastra C, Morbiducci U, Ali ZA, Spratt JC, Ando H, Amano T, Kitslaar P, Wilgenhof A, Sonck J, De Bruyne B, Collet C. Advanced CT Imaging for the Assessment of Calcific Coronary Artery Disease and PCI Planning. J Soc Cardiovasc Angiogr Interv. 2024 Mar 26;3(3Part B):101299. doi: 10.1016/j.jscai.2024.101299. eCollection 2024 Mar.
- Monizzi G, Sonck J, Nagumo S, Buytaert D, Van Hoe L, Grancini L, Bartorelli AL, Vanhoenacker P, Simons P, Bladt O, Wyffels E, De Bruyne B, Andreini D, Collet C. Quantification of calcium burden by coronary CT angiography compared to optical coherence tomography. Int J Cardiovasc Imaging. 2020 Dec;36(12):2393-2402. doi: 10.1007/s10554-020-01839-z. Epub 2020 Nov 17.
- Collet C, Collison D, Mizukami T, McCartney P, Sonck J, Ford T, Munhoz D, Berry C, De Bruyne B, Oldroyd K. Differential Improvement in Angina and Health-Related Quality of Life After PCI in Focal and Diffuse Coronary Artery Disease. JACC Cardiovasc Interv. 2022 Dec 26;15(24):2506-2518. doi: 10.1016/j.jcin.2022.09.048. Epub 2022 Nov 30.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- EPIC46-THE OPTIMAL TRIAL
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .